MTOR and breast cancer: The signaling pathway involved in cell proliferation and survival, phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) or (PI3K/AKT/mTOR), is often dysregulated in breast cancer and is associated with endocrine therapy resistance [39].